Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Patent
1994-03-28
1997-03-25
Mosher, Mary E.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
4241991, 4242041, 4242321, 4352351, 4353201, 935 65, A61K 39285, A61K 3912, C12N 701
Patent
active
056141939
ABSTRACT:
Vaccine formulations for inducing protective immune response to Hantaviruses in humans are disclosed. These formulations include an attenuated vaccinia virus vector containing cDNA's encoding Hantavirus nucleocapsid N protein, G1 and G2 glycoproteins. Methods for the use of these formulations also are disclosed.
REFERENCES:
Lee et al. "Isolation of the Etiologic Agent of Korean Hemorrhagic Fever", . Infect. Dis. 137:298-307 (1978).
Schmaljohn and Dalrymple "Analysis of Hantaan Virus RNA: Evidence for a New Genus of Bunyavirdae", Virology 131:482-491 (1983).
Schmaljohn et al. "Coding Strategy of the S Genome Segment of Hantaan Virus", Virology 155:633-643 (1986).
Schmaljohn et al. "Hantaan Virus M RNA: Coding Strategy, Nucleotide Sequence, and Gene Order", Virology 157:31-39 (1987).
Yoo and Kang "Nucleotide sequence of the M segment of the genomic RNA of Hantaan virus 76-118", Nuc. Acids Res. 15:6299-6300 (1987).
Schmaljohn et al. "Baculovirus Expression of the Small Genome Segment of Hantaan Virus and Potential Use of the Expressed Nucleocapsid Protein . . . ", J. Gen. Virol. 69:777-786 (1988).
Rossi et al. "Diagnostic potential of a baculovirus-expressed nucleocapsid protein for hantaviruses", Arch. Virol. S1:19-28 (1990).
Schmaljohn et al. "Antigenic Subunits of Hantaan Virus Expressed by Baculovirus and Vaccinia Virus Recombinants", J. Virol. 64:3162-3170 (1990).
Schmaljohn et al. "Preparation of candidate vaccinia-vectored vaccines for haemorrhagic fever with renal syndrome", Vaccine 10:10-13 (1992).
Hsiang, C.M. 1989, Virus Genes vol. 2 pp. 367-369.
Tartaglia, J. et al, 1990. Crit Rev. Immunol. vol. 10 pp. 13-30.
Xu, X. et al. Am. J. Trop. Med. Hyg. vol. 47 pp. 397-404.
Dalrymple, deceased Joel
McClain David J.
Schmaljohn Connie S.
Moran John Francis
Mosher Mary E.
The United States of America as represented by the Secretary of
LandOfFree
Hantavirus vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hantavirus vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hantavirus vaccine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2201128